MedTrace Logo

Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters

NCT00882011 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-10-13

No results posted yet for this study

Summary

The purpose of the study is to create a prospective database of T-Lymphoblastic Lymphoma (T-LBL) cases in order to conduct an appropriate statistical study as well as to monitor diagnosis and minimal residual disease (MRD), to detect specific genetic profile useful to give advices on therapies, to assess if PET has a prognostic validity on T-Lymphoblastic Lymphoma (T-LBL).

Conditions

  • Lymphoblastic Lymphoma

Interventions

OTHER

Latest generation chemotherapies for T-LBL + transplant

1. Standard doses of one of the following chemotherapies: * Holzer * LSA2-L2 modified * Stanford regimen * Hyper CVAD * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others) * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial) 2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Massimo Federico, MD · Azienda Ospedaliero-Universitaria di Modena (MO)

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2014-04-30
Completion
2019-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00882011 on ClinicalTrials.gov